USD10
MOLN Shares
About Molecular PartnersMolecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
USD10
MOLN Shares
About Molecular PartnersMolecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$171.48M
OPEN PRICE
$4.68
LOW (1Y)
$3.36
HIGH (1Y)
$5.36
LOW (24H)
$4.39
HIGH (24H)
$4.72
VOLUME (24H)
$2.69K
43.88%
Price history
Time | Price | Change |
|---|---|---|
Today | $4.68 | |
1 Day | $4.59 | 0.00% |
1 Week | $4.25 | |
1 Month | $4.98 | |
1 Year | $3.90 |